North America PCR for Respiratory Infection Diagnostics Market
Polymerase chain reaction (PCR) is used for accurate point of care diagnostics that help rapidly identify and determine the cause of respiratory tract infections. In addition, PCR is widely preferred in inpatient and outpatient settings that help enhance the growth of the market in recent years.
Strategic insights for the North America PCR for Respiratory Infection Diagnostics provides data-driven analysis of the industry landscape, including current trends, key players, and regional nuances. These insights offer actionable recommendations, enabling readers to differentiate themselves from competitors by identifying untapped segments or developing unique value propositions. Leveraging data analytics, these insights help industry players anticipate the market shifts, whether investors, manufacturers, or other stakeholders. A future-oriented perspective is essential, helping stakeholders anticipate market shifts and position themselves for long-term success in this dynamic region. Ultimately, effective strategic insights empower readers to make informed decisions that drive profitability and achieve their business objectives within the market.
| Report Attribute | Details |
|---|---|
| Market size in 2021 | US$ 1,766.10 Million |
| Market Size by 2028 | US$ 3,581.63 Million |
| Global CAGR (2021 - 2028) | 10.6% |
| Historical Data | 2019-2020 |
| Forecast period | 2022-2028 |
| Segments Covered |
By Type
|
| Regions and Countries Covered | North America
|
| Market leaders and key company profiles |
The geographic scope of the North America PCR for Respiratory Infection Diagnostics refers to the specific areas in which a business operates and competes. Understanding local distinctions, such as diverse consumer preferences (e.g., demand for specific plug types or battery backup durations), varying economic conditions, and regulatory environments, is crucial for tailoring strategies to specific markets. Businesses can expand their reach by identifying underserved areas or adapting their offerings to meet local demands. A clear market focus allows for more effective resource allocation, targeted marketing campaigns, and better positioning against local competitors, ultimately driving growth in those targeted areas.
The North America PCR for respiratory infection diagnostics market is expected to reach US$ 3,581.63 million by 2028 from US$ 1,766.10 million in 2021; it is estimated to grow at a CAGR of 10.6% from 2021 to 2028. The growth of the market is attributed to some of the key driving factors such as increasing developments in PCR technology and rising use of PCR testing for various respiratory infection diagnostics. However, availability of alternative assays is the major factor hindering the market growth.
Chronic respiratory diseases (CRDs) are among the leading causes of morbidity globally due to the heavy consumption of tobacco. For instance, according to the WHO, in 2018, the fourth largest cause of mortality in the US was chronic lower respiratory illness, predominantly COPD. Nearly 15.7 million Americans (6.4%) have been diagnosed with COPD. The burden of CRDs is expected to increase in the future due to poor air quality, increase in addiction to smoking, and rise in geriatric population that is more prone to COPD and lung cancer. Moreover, programs initiated in the countries to improve treatment and support the people living with respiratory diseases are likely to increase the demand for PCR for the diagnosis of respiratory diseases. This will lead to the market growth during the forecast period. The demand for PCR testing to diagnose infectious diseases has significantly risen in the past few years. The growing technological advancements have added an extra advantage of point-of-care testing through PCR, which has surged the demand for PCR diagnostics. In addition, the demand has exponentially raised due to the outbreak of COVID-19. Since the pandemic has initiated, reverse transcription-polymerase reaction (RT-PCR) test has been preferably used to diagnose and examine the genetic material of SARS-CoV-2 RNA. The RT-PCR method is widely accepted as the gold standard for the detection of SARS-CoV-2 RNA due to its sensitive testing. Therefore, considering the demand for PCR testing, various market players have introduced PCR products and entered strategic developments in the global market. Also, most companies are now offering real-time polymerase chain reaction (PCR) tests for COVID-19, which is contributing to the growth of the target market.
COVID-19 pandemic has served vital growth opportunities for the PCR for respiratory infection diagnostics market. The market has experienced exponential growth during the pandemic due to tremendous demand for COVID-19 testing through PCR. North America is the leading market that has significantly contributed to the growth of the market. There have been various factors, including increased incidences of COVID-19 positive patients, growth in PCR technologies, increasing production of reagents and kits, and many other factors. The cases majorly led to the demand for PCR testing in the countries such as the US, Canada, and Mexico. In addition, companies such as Omega Laboratories and LaunchWorks are launching various PCR testing in countries expanding the services, due to increasing demand from governments, communities, and organizations to track and control the spread of the virus.
Based on type, the North America PCR for respiratory infection diagnostics market is segmented into real time PCR (qPCR), traditional PCR, reverse-transcriptase (RT-PCR), digital PCR, multiplex PCR, and others. The real-time PCR (qPCR) segment held the largest share of the market in 2021 and is anticipated to register the highest CAGR in the market during the forecast period.
Based on product type, the North America PCR for respiratory infection diagnostics market is segmented into reagents and kits, instruments, and others. The reagents and kits segment held the largest share of the market in 2021 and is anticipated to register the highest CAGR in the market during the forecast period.
A few of the primary and secondary sources associated with this report on the North America PCR for respiratory infection diagnostics market are Ministry of Health (MoH), Food and Drug Administration (FDA) and Centers for Disease Control and Prevention (CDC).
The North America PCR for Respiratory Infection Diagnostics Market is valued at US$ 1,766.10 Million in 2021, it is projected to reach US$ 3,581.63 Million by 2028.
As per our report North America PCR for Respiratory Infection Diagnostics Market, the market size is valued at US$ 1,766.10 Million in 2021, projecting it to reach US$ 3,581.63 Million by 2028. This translates to a CAGR of approximately 10.6% during the forecast period.
The North America PCR for Respiratory Infection Diagnostics Market report typically cover these key segments-
The historic period, base year, and forecast period can vary slightly depending on the specific market research report. However, for the North America PCR for Respiratory Infection Diagnostics Market report:
The North America PCR for Respiratory Infection Diagnostics Market is populated by several key players, each contributing to its growth and innovation. Some of the major players include:
The North America PCR for Respiratory Infection Diagnostics Market report is valuable for diverse stakeholders, including:
Essentially, anyone involved in or considering involvement in the North America PCR for Respiratory Infection Diagnostics Market value chain can benefit from the information contained in a comprehensive market report.
Office No. 1011, First floor, Farena Corporate Park, Magarpatta-Mundhwa road, Pune - 411028, Maharashtra, India
US:+16467917070
sales@businessmarketinsights.com
Get Free Sample For North America PCR for Respiratory Infection Diagnostics Market
